Sera Prognostics (NASDAQ:SERA) CFO Sells $15,905.28 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,232 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $3.04, for a total value of $15,905.28. Following the sale, the chief financial officer directly owned 273,087 shares of the company’s stock, valued at $830,184.48. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Austin Aerts also recently made the following trade(s):

• On Thursday, September 11th, Austin Aerts sold 915 shares of Sera Prognostics stock. The shares were sold at an average price of $3.13, for a total transaction of $2,863.95.

Sera Prognostics Trading Up 10.7%

Shares of NASDAQ:SERA traded up $0.33 during trading on Wednesday, hitting $3.40. 121,326 shares of the company’s stock were exchanged, compared to its average volume of 29,844. The firm has a market cap of $131.24 million, a P/E ratio of -4.42 and a beta of 0.97. The firm has a 50-day moving average price of $3.18 and a two-hundred day moving average price of $2.79. Sera Prognostics, Inc. has a 1-year low of $1.37 and a 1-year high of $9.13.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, research analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

SERA has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. Wall Street Zen upgraded Sera Prognostics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Sera Prognostics

Several hedge funds have recently added to or reduced their stakes in SERA. AWM Investment Company Inc. grew its stake in Sera Prognostics by 48.1% in the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company’s stock valued at $3,190,000 after acquiring an additional 281,703 shares during the period. Ghisallo Capital Management LLC bought a new position in shares of Sera Prognostics during the 1st quarter valued at about $368,000. Aberdeen Group plc acquired a new position in shares of Sera Prognostics in the 1st quarter valued at approximately $4,563,000. Sanders Morris Harris LLC increased its stake in Sera Prognostics by 179.8% during the 2nd quarter. Sanders Morris Harris LLC now owns 263,600 shares of the company’s stock worth $730,000 after purchasing an additional 169,400 shares in the last quarter. Finally, Wagner Wealth Management LLC acquired a new stake in Sera Prognostics during the 2nd quarter worth approximately $34,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.